Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4468883 | 0.93 | PDE5A (0.60) | PDE5AKCNH2 | |
| SCHEMBL4467131 | 0.89 | PDE5A (0.58) | PDE5AKCNH2 | |
| SCHEMBL4463898 | 0.88 | PDE5A (0.60) | PDE5AKCNH2 | |
| SCHEMBL4455094 | 0.87 | PDE5A (0.63) | PDE5AKCNH2 | |
| SCHEMBL4702131 | 0.85 | PDE5A (0.64) | PDE5AKCNH2 | |
| SCHEMBL4702163 | 0.84 | PDE5A (0.71) | PDE5AKCNH2 | |
| SCHEMBL4468497 | 0.83 | PDE5A (0.62) | PDE5AKCNH2 | |
| SCHEMBL4701226 | 0.83 | PDE5A (0.61) | PDE5AKCNH2 | |
| SCHEMBL4473860 | 0.82 | PDE5A (0.57) | PDE5AKCNH2 | |
| SCHEMBL4466212 | 0.81 | PDE5A (0.57) | PDE5AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7569572-B2 | Pyrazolo[4,3-D]pyrimidines | PFIZER INC (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1742950-B1 | PYRAZOLO[4,3-D] PYRIMIDINES | PFIZER LTD (GB) | 2008-12-17 | — | — | EP | disclosed |
| US-20080293697-A1 | Pyrazolo[4,3-D]Pyrimidines | BELL ANDREW SIMON | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293697-A1 | Pyrazolo[4,3-D]Pyrimidines | DPYD, TYMS, TYMP | PDE5A 1707/4885KCNH2 794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.